Figure 2From: FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study Kaplan-Meier survival analysis of progression-free survival (A) and overall survival (B) from the start of FOLFOX second-line chemotherapy according to ECOG PS status (0–1, solid dark line) (2–3, dashed dark line). Back to article page